Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.5401
0.00 (0.00%)
Jul 29, 2026, 9:41 AM EDT - Market open
Lexaria Bioscience Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 0.19 | 0.71 | 0.46 | 0.23 | 0.26 | 0.72 | |
Revenue Growth | -68.50% | 52.05% | 105.24% | -11.43% | -64.66% | 129.59% |
Cost of Revenue | - | 0 | 0 | 0.03 | 0.07 | 0.18 |
Gross Profit | 0.19 | 0.7 | 0.46 | 0.19 | 0.18 | 0.55 |
Selling, General & Admin | 3.9 | 4.35 | 3.85 | 3.06 | 4.96 | 4.97 |
Research & Development | 4 | 8.24 | 2.36 | 3.67 | 1.84 | 1.26 |
Total Operating Expenses | 7.9 | 12.58 | 6.21 | 6.73 | 6.8 | 6.23 |
Operating Income | -7.71 | -11.88 | -5.75 | -6.53 | -6.62 | -5.69 |
Interest Income | 0.01 | 0 | 0.01 | 0.04 | - | - |
Other Non-Operating Income (Expense) | -0.03 | -0.03 | -0.07 | -0.22 | -0.76 | 1.52 |
Total Non-Operating Income (Expense) | -0.03 | -0.03 | -0.06 | -0.18 | -0.76 | 1.52 |
Pretax Income | -5.04 | -11.91 | -5.81 | -6.71 | -7.38 | -4.16 |
Net Income | -5.04 | -11.91 | -5.81 | -6.71 | -7.38 | -4.16 |
Minority Interest in Earnings | 0.01 | 0.01 | 0.01 | 0.05 | 0.11 | 0.16 |
Earnings From Discontinued Operations | - | - | - | - | - | -0.02 |
Net Income to Common | -7.73 | -11.9 | -5.8 | -6.66 | -7.27 | -4.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 18 | 12 | 7 | 6 | 4 |
Shares Outstanding (Diluted) | 23 | 18 | 12 | 7 | 6 | 4 |
Shares Change | 32.28% | 45.34% | 87.24% | 12.38% | 34.02% | 58.34% |
EPS (Basic) | -0.34 | -0.66 | -0.47 | -1.01 | -1.24 | -0.95 |
EPS (Diluted) | -0.34 | -0.66 | -0.47 | -1.01 | -1.24 | -0.95 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Free Cash Flow | -7.47 | -10.48 | -5 | -5.91 | -4.93 | -3.99 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.33 | -0.58 | -0.40 | -0.89 | -0.84 | -0.91 |
Gross Margin | 100.00% | 99.61% | 98.96% | 86.07% | 71.87% | 75.74% |
Operating Margin | -3973.16% | -1683.01% | -1239.16% | -2888.50% | -2591.67% | -786.85% |
Profit Margin | -2597.33% | -1687.36% | -1251.12% | -2967.41% | -2891.05% | -576.16% |
FCF Margin | -3848.61% | -1483.88% | -1077.38% | -2614.84% | -1929.75% | -552.02% |
EBITDA | -7.63 | -11.79 | -5.68 | -6.39 | -6.52 | -5.58 |
EBITDA Margin | -3933.69% | -1670.57% | -1222.75% | -2824.23% | -2551.45% | -771.39% |
EBIT | -7.71 | -11.88 | -5.75 | -6.53 | -6.62 | -5.69 |
EBIT Margin | -3973.16% | -1683.01% | -1239.16% | -2888.50% | -2591.67% | -786.85% |